Patents by Inventor Erin Sult
Erin Sult has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340152Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: November 30, 2022Publication date: October 26, 2023Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 11525012Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: November 8, 2019Date of Patent: December 13, 2022Assignee: MedImmune LimitedInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Patent number: 10864269Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.Type: GrantFiled: September 25, 2017Date of Patent: December 15, 2020Assignee: MedImmune LimitedInventors: Kris Sachsenmeier, Erin Sult, Carl Hay, Edmund Poon
-
Publication number: 20200079877Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: November 8, 2019Publication date: March 12, 2020Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 10556968Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: April 4, 2019Date of Patent: February 11, 2020Assignee: MEDIMMUNE LIMITEDInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20190292274Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: April 4, 2019Publication date: September 26, 2019Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui HUANG, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 10287362Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: February 23, 2018Date of Patent: May 14, 2019Assignee: MedImmune LimitedInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20180194858Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: February 23, 2018Publication date: July 12, 2018Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Publication number: 20180125973Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MED19447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.Type: ApplicationFiled: September 25, 2017Publication date: May 10, 2018Applicant: MedImmune LimitedInventors: Kris SACHSENMEIER, Erin SULT, Carl HAY, Edmund POON
-
Patent number: 9938356Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: November 9, 2015Date of Patent: April 10, 2018Assignee: MEDIMMUNE LIMITEDInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20160194407Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: November 9, 2015Publication date: July 7, 2016Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20160129108Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.Type: ApplicationFiled: November 10, 2015Publication date: May 12, 2016Applicant: MedImmune LimitedInventors: Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon